CoChat
Sign Up
Cited by 95Treatment of Major DepressionTranscranial Magnetic Stimulation StudiesElectroconvulsive Therapy Studies

Leveraging Neuroplasticity to Enhance Adaptive Learning: The Potential for Synergistic Somatic-Behavioral Treatment Combinations to Improve Clinical Outcomes in Depression

Open access
Wilkinson, Samuel T., Holtzheimer, Paul E., Gao, Shan, Kirwin, David S., Price, Rebecca B.·2019·Biological Psychiatry
DOI 10.1016/j.biopsych.2018.09.004PMC PMC6380941
Open this paper in CoChat — free account

Abstract

Until recently, therapeutic development in psychiatry was targeted solely toward symptom reduction. While this is a worthwhile goal, it has yielded little progress in improved therapeutics in the last several decades in the field of mood disorders. Recent advancements in our understanding of pathophysiology suggests that an impairment of neuroplasticity may be a critical part of the development of neuropsychiatric disorders. Interventions that enhance or modulate neuroplasticity often reduce depressive symptoms when applied as stand-alone treatments. Unfortunately, when treatments are discontinued, the disease state often returns as patients relapse. However, treatments that enhance or modulate plasticity not only reduce symptom burden, but also may provide an opportune window wherein cognitive or behavioral interventions could be introduced to harness a state of enhanced neuroplasticity and lead to improved longer-term clinical outcomes. Here, we review the potential of synergistically combining plasticity-enhancing and behavioral therapies to develop novel translational treatment approaches for depression. After reviewing relevant neuroplasticity deficits in depression, we survey biological treatments that appear to reverse such deficits in humans, including N-methyl-D-aspartate receptor modulators (ketamine, D-cycloserine), electroconvulsive therapy, and transcranial brain stimulation. We then review evidence that either directly or indirectly supports the hypothesis that a robust enhancement of neuroplasticity through these methods might promote the uptake of cognitive and behavioral interventions to enhance longer-term treatment outcomes through a synergistic effect. We identify key missing pieces of evidence and discuss future directions to enhance this emerging line of research.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.biopsych.2018.09.004

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Pharmacogenomic tools add a complementary layer for medication selection, with multiple blinded trials and meta-analyses showing modest yet reliable gains in response and remission, particularly when switching to genetically congruent agents, thereby enriching strata and reducing futile exposure.

    “Pharmacogenomic tools add a complementary layer for medication selection, with multiple blinded trials and meta-analyses showing modest yet reliable gains in response and remission, particularly when switching to genetically congruent agents, thereby enriching strata and reducing futile exposure [409,410].”

    From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [410]

    Split into 2 atoms — 0 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 2 unverifiable. Expand the claim to see per-atom verdicts.

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 109

  1. [1]Abdallah CG, Sanacora G, Duman RS, Krystal JH (2015): Ketamine and rapid-acting antidepressants: A window into a new neurobiology for mood disorder therapeutics. Annu Rev Med 66: 509– 523. 25341010 PMC4428310
  2. [2]Duman RS, Aghajanian GK, Sanacora G, Krystal JH (2016): Synaptic plasticity and depression: New insights from stress and rapid-acting antidepressants. Nat Med 22: 238– 249. 26937618 PMC5405628
  3. [3]Castren E (2013): Neuronal network plasticity and recovery from depression. JAMA Psychiatry 70: 983– 989. 23842648
  4. [4]Sharpley CF (2010): A review of the neurobiological effects of psychotherapy for depression. Psychotherapy (Chic) 47: 603– 615. 21198246
  5. [5]Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M, (2010): mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329: 959– 964. 20724638 PMC3116441
  6. [6]Cornwell BR, Salvadore G, Furey M, Marquardt CA, Brutsche NE, Grillon C, (2012): Synaptic potentiation is critical for rapid antidepressant response to ketamine in treatment-resistant major depression. Biol Psychiatry 72: 555– 561. 22521148 PMC3408548
  7. [7]Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, (2000): Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47: 351– 354. 10686270
  8. [8]Zanos P, Moaddel R, Morris PJ, Georgiou P, Fischell J, Elmer GI, (2016): NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature 533: 481– 486. 27144355 PMC4922311
  9. [9]Hoogendam JM, Ramakers GM, Di Lazzaro V (2010): Physiology of repetitive transcranial magnetic stimulation of the human brain. Brain Stimul 3: 95– 118. 20633438
  10. [10]Dukart J, Regen F, Kherif F, Colla M, Bajbouj M, Heuser I, (2014): Electroconvulsive therapy-induced brain plasticity determines therapeutic outcome in mood disorders. Proc Natl Acad Sci U S A 111: 1156– 1161. 24379394 PMC3903198
  11. [12]Simon GE, Von Korff M, Rutter CM, Peterson DA (2001): Treatment process and outcomes for managed care patients receiving new antidepressant prescriptions from psychiatrists and primary care physicians. Arch Gen Psychiatry 58: 395– 401. 11296101
  12. [14]Hollon SD, Stewart MO, Strunk D (2006): Enduring effects for cognitive behavior therapy in the treatment of depression and anxiety. Annu Rev Psychol 57: 285– 315. 16318597
  13. [15]Hollon SD, DeRubeis RJ, Shelton RC, Amsterdam JD, Salomon RM, O’Reardon JP, (2006): Prevention of relapse following cognitive therapy vs medications in moderate to severe depression. Arch Gen Psychiatry 62: 417– 422. 15809409
  14. [17]Castrén E (2005): Is mood chemistry? Nat Rev Neurosci 6: 241– 246. 15738959
  15. [18]Castren E, Hen R (2013): Neuronal plasticity and antidepressant actions. Trends Neurosci 36: 259– 267. 23380665 PMC3648595
  16. [19]Changeaux JP, Danchin A (1976): Selective stabilization of developing synapses as a mechanism for the specification of neuronal networks. Nature 264: 705– 712. 189195
  17. [21]Stange JP, Connolly SL, Burke TA, Hamilton JL, Hamlat EJ, Abramson LY, (2016): Inflexible cognition predicts first onset of major depressive episodes in adolescence. Depress Anxiety 33: 1005– 1012. 27093215 PMC5071106
  18. [24]Price RB, Eldreth DA, Mohlman J (2011): Deficient prefrontal attentional control in late-life generalized anxiety disorder: An fMRI investigation. Transl Psychiatry 1: e46. 22833192 PMC3309492
  19. [25]Disner S, Beevers C, Haigh EAP, Beck AT (2011): Neural mechanisms of the cognitive model of depression. Nat Rev Neurosci 12: 467– 477. 21731066
  20. [26]Price RB, Allen KB, Silk JS, Ladouceur CD, Ryan ND, Dahl RE, (2016): Vigilance in the laboratory predicts avoidance in the real world: A dimensional analysis of neural, behavioral, and ecological momentary data in anxious youth. Dev Cogn Neurosci 19: 128– 136. 27010577 PMC4912858
  21. [29]de Raedt R, Koster EHW (2010): Understanding vulnerability for depression from a cognitive neuroscience perspective: A reappraisal of attentional factors and a new conceptual framework. Cogn Affect Behav Neurosci 10: 50– 70. 20233955
  22. [30]Bar-Haim Y, Lamy D, Pergamin L, Bakermans-Kranenburg MJ, van IJzendoorn MH (2007): Threat-related attentional bias in anxious and nonanxious individuals: A meta-analytic study. Psychol Bull 133: 1– 24. 17201568
  23. [33]Craighead WE, Dunlop BW (2014): Combination psychotherapy and antidepressant medication treatment for depression: For whom, when, and how. Annu Rev Psychol 65: 267– 300. 24405361
  24. [34]Cuijpers P, Dekker J, Hollon SD, Andersson G (2009): Adding psychotherapy to pharmacotherapy in the treatment of depressive disorders in adults: A meta-analysis. J Clin Psychiatry 70: 1219– 1229. 19818243
  25. [35]Ishak WW, Ha K, Kapitanski N, Bagot K, Fathy H, Swanson B, (2011): The impact of psychotherapy, pharmacotherapy, and their combination on quality of life in depression. Harv Rev Psychiatry 19: 277– 289. 22098324
  26. [37]Caddy C, Amit BH, McCloud TL, Rendell JM, Furukawa TA, McShane R, (2015): Ketamine and other glutamate receptor modulators for depression in adults. Cochrane Database Syst Rev (9): CD011612. 26395901
  27. [39]aan het Rot M, Collins KA, Murrough JW, Perez AM, Reich DL, Charney DS, (2010): Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry 67: 139– 145. 19897179
  28. [40]Murrough JW, Perez AM, Pillemer S, Stern J, Parides MK, Aan Het Rot M, (2013): Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry 74: 250– 256. 22840761 PMC3725185
  29. [41]Rasmussen KG, Lineberry TW, Galardy CW, Kung S, Lapid MI, Palmer BA, (2013): Serial infusions of low-dose ketamine for major depression. J Psychopharmacol 27: 444– 450. 23428794
  30. [42]Wilkinson S, Toprak M, Turner M, Levine S, Katz R, Sanacora G (2017): A survey of the clinical, off-label use of ketamine as a treatment for psychiatric disorders. Am J Psychiatry 174: 695– 696. 28669202 PMC5549850
  31. [43]Schatzberg AF (2014): A word to the wise about ketamine. Am J Psychiatry 171: 262– 264. 24585328
  32. [44]Morgan CJ, Curran HV; Independent Scientific Committee on Drugs (2012): Ketamine use: A review. Addiction 107: 27– 38. 21777321
  33. [46]Nagy D, Stoiljkovic M, Menniti FS, Hajos M (2015): Differential effects of an NR2B NAM and ketamine on synaptic potentiation and gamma synchrony: Relevance to rapid-onset antidepressant efficacy. Neuropsychopharmacology 41: 1486– 1494. 26404843 PMC4832008
  34. [47]Abdallah CG, Averill LA, Collins KA, Geha P, Schwartz J, Averill C, (2017): Ketamine treatment and global brain connectivity in major depression. Neuropsychopharmacology 42: 1210– 1219. 27604566 PMC5437875
  35. [48]Lv Q, Yang L, Li G, Wang Z, Shen Z, Yu W, (2016): Large-scale persistent network reconfiguration induced by ketamine in anesthetized monkeys: Relevance to mood disorders. Biol Psychiatry 79: 765– 775. 25837427
  36. [49]Murrough JW, Burdick KE, Levitch CF, Perez AM, Brallier JW, Chang LC, (2014): Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: A randomized controlled trial. Neuropsychopharmacology 40: 1084– 1090. PMC4367458 25374095
  37. [51]Shiroma PR, Albott CS, Johns B, Thuras P, Wels J, Lim KO (2014): Neurocognitive performance and serial intravenous subanesthetic ketamine in treatment-resistant depression. Int J Neuropsychopharmacology 17: 1805– 1813. 24963561
  38. [52]Featherstone RE, Liang Y, Saunders JA, Tatard-Leitman VM, Ehrlichman RS, Siegel SJ (2012): Subchronic ketamine treatment leads to permanent changes in EEG, cognition and the astrocytic glutamate transporter EAAT2 in mice. Neurobiol Dis 47: 338– 346. 22627142
  39. [53]Morgan CJ, Muetzelfeldt L, Curran HV (2009): Ketamine use, cognition and psychological wellbeing: A comparison of frequent, infrequent and ex-users with polydrug and non-using controls. Addiction 104: 77– 87. 19133891
  40. [54]Price RB, Iosifescu DV, Murrough JW, Chang LC, Al Jurdi RK, Iqbal SZ, (2014): Effects of ketamine on explicit and implicit suicidal cognition: A randomized controlled trial in treatment-resistant depression. Depress Anxiety 31: 335– 343. 24668760 PMC4112410
  41. [56]Murrough JW, Collins KA, Fields J, DeWilde KE, Phillips ML, Mathew SJ, (2015): Regulation of neural responses to emotion perception by ketamine in individuals with treatment-resistant major depressive disorder. Transl Psychiatry 5: e509. 25689570 PMC4445748
  42. [58]Downey D, Dutta A, McKie S, Dawson GR, Dourish CT, Craig K, (2016): Comparing the actions of lanicemine and ketamine in depression: Key role of the anterior cingulate. Eur Neuropsychopharmacol 26: 994– 1003. 27133029
  43. [59]Nugent AC, Robinson SE, Coppola R, Zarate CA Jr (2016): Preliminary differences in resting state MEG functional connectivity preand post-ketamine in major depressive disorder. Psychiatry Res 254: 56– 66. PMC4992587 27362845
  44. [60]Kaiser RH, Andrews-Hanna JR, Wager TD, Pizzagalli DA (2015): Large-scale network dysfunction in major depressive disorder: A meta-analysis of resting-state functional connectivity. JAMA Psychiatry 72: 603– 611. 25785575 PMC4456260
  45. [61]Baudry M, Bi X, Gall C, Lynch G (2011): The biochemistry of memory: The twenty-six year journey of a “new and specific hypothesis201D. Neurobiol Learn Mem 95: 125– 133. 21134478 PMC3042723
  46. [62]Ramirez A, Arbuckle MR (2016): Synaptic plasticity: The role of learning and unlearning in addiction and beyond. Biol Psychiatry 80: e73– e75. 27697156 PMC5347979
  47. [63]Wilkinson ST, Wright D, Fasula MK, Fenton L, Griepp M, Ostroff RB, (2017): Cognitive behavior therapy may sustain antidepressant effects of intravenous ketamine in treatment-resistant depression. Psychother Psychosom 86: 162– 167. 28490030 PMC5516265
  48. [64]Shiroma PR, Johns B, Kuskowski M, Wels J, Thuras P, Albott CS, (2014): Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment resistant depression. J Affect Disord 155: 123– 129. 24268616
  49. [67]Mogoaşe C, David D, Koster EHW (2014): Clinical efficacy of attentional bias modification procedures: An updated meta-analysis. J Clin Psychol 70: 1133– 1157. 24652823
  50. [68]Hofmann W, De Houwer J, Perugini M, Baeyens F, Crombez G (2010): Evaluative conditioning in humans: A meta-analysis. Psychol Bull 136: 390– 421. 20438144
  51. [69]Rodriguez CI, Wheaton M, Zwerling J, Steinman SA, Sonnenfeld D, Galfalvy H, (2016): Can exposure-based CBT extend the effects of intravenous ketamine in obsessive-compulsive disorder? An open-label trial. J Clin Psychiatry 77: 408– 409. 27046314 PMC5544939
  52. [70]Pradhan B, Mitrev L, Moaddell R, Wainer IW (2018): d-Serine is a potential biomarker for clinical response in treatment of post-traumatic stress disorder using (R,S)-ketamine infusion and TIMBER psychotherapy: A pilot study. Biochim Biophys Acta 1866: 831– 839. PMC9067607 29563072
  53. [72]Heresco-Levy U, Gelfin G, Bloch B, Levin R, Edelman S, Javitt DC, (2013): A randomized add-on trial of high-dose D-cycloserine for treatment-resistant depression. Int J Neuropsychopharmacol 16: 501– 506. 23174090
  54. [73]Kantrowitz JT, Halberstam B, Gangwisch J (2015): Single-dose ketamine followed by daily D-Cycloserine in treatment-resistant bipolar depression. J Clin Psychiatry 76: 737– 738. 26132675
  55. [74]Onur OA, Schlaepfer TE, Kukolja J, Bauer A, Jeung H, Patin A, (2010): The N-methyl-D-aspartate receptor co-agonist D-cycloserine facilitates declarative learning and hippocampal activity in humans. Biol Psychiatry 67: 1205– 1211. 20303474
  56. [75]Krystal JH, Tolin DF, Sanacora G, Castner SA, Williams GV, Aikins DE, (2009): Neuroplasticity as a target for the pharmacotherapy of anxiety disorders, mood disorders, and schizophrenia. Drug Discov Today 14: 690– 697. 19460458 PMC2898127
  57. [78]Otto MW, Lee J, Hofmann SG, Hearon BA, Smits JA, Rosenfield D, (2016): Examining the efficacy of d-cycloserine to augment therapeutic learning in depression. Contemp Clin Trials 48: 146– 152. 27094721 PMC10999219
  58. [79]Greenberg RM, Kellner CH (2005): Electroconvulsive therapy: A selected review. Am J Geriatr Psychiatry 13: 268– 281. 15845752
  59. [80]Zisook S, Ganadjian K, Moutier C, Prather R, Rao S (2008): Sequenced Treatment Alternatives to Relieve Depression (STAR*D): Lessons learned. J Clin Psychiatry 69: 1184– 1185. 18687018
  60. [81]Weiner R, Coffey C, Fochtmann L, Greenberg R, Isenberg K, Kellner C, (2001): The Practice of Electroconvulsive Therapy. Recommendations for Treatment, Training, and Privileging: A Task Force Report of the American Psychiatric Association, 2nd ed. Washington, DC: American Psychiatric Press.
  61. [82]Kellner CH, Knapp RG, Petrides G, Rummans TA, Husain MM, Rasmussen K, (2006): Continuation electroconvulsive therapy vs pharmacotherapy for relapse prevention in major depression: A multisite study from the Consortium for Research in Electroconvulsive Therapy (CORE). Arch Gen Psychiatry 63: 1337– 1344. 17146008 PMC3708140
  62. [83]Kellner CH, Husain MM, Knapp RG, McCall WV, Petrides G, Rudorfer MV, (2016): Right unilateral ultrabrief pulse ECT in geriatric depression: Phase 1 of the PRIDE study. Am J Psychiatry 173: 1101– 1109. 27418379 PMC7130447
  63. [85]Wilkinson ST, Sanacora G, Bloch MH (2017): Hippocampal volume changes following electroconvulsive therapy: A systematic review and meta-analysis. Biol Psychiatry Cogn Neurosci Neuroimaging 2: 327– 335. 28989984 PMC5627663
  64. [86]Svensson M, Grahm M, Ekstrand J, Hoglund P, Johansson M, Tingstrom A (2016): Effect of electroconvulsive seizures on cognitive flexibility. Hippocampus 26: 899– 910. 26850212
  65. [87]Nordanskog P, Larsson MR, Larsson EM, Johanson A (2014): Hippocampal volume in relation to clinical and cognitive outcome after electroconvulsive therapy in depression. Acta Psychiatr Scand 129: 303– 311. 23745780 PMC4226425
  66. [89]Mulders PC, van Eijndhoven PF, Pluijmen J, Schene AH, Tendolkar I, Beckmann CF (2016): Default mode network coherence in treatment-resistant major depressive disorder during electroconvulsive therapy. J Affect Disord 205: 130– 137. 27434117
  67. [90]Sackeim HA, Haskett RF, Mulsant BH, Thase ME, Mann JJ, Pettinati HM, (2001): Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: A randomized controlled trial. JAMA 285: 1299– 1307. 11255384
  68. [92]Sackeim HA, Prudic J, Nobler MS, Fitzsimons L, Lisanby SH, Payne N, (2008): Effects of pulse width and electrode placement on the efficacy and cognitive effects of electroconvulsive therapy. Brain Stimul 1: 71– 83. 19756236 PMC2742986
  69. [93]McClintock SM, Brandon AR, Husain MM, Jarrett RB (2011): A systematic review of the combined use of electroconvulsive therapy and psychotherapy for depression. J ECT 27: 236– 243. 21206376 PMC3162076
  70. [94]McCall WV, Dunn A, Rosenquist PB, Hughes D (2002): Markedly suprathreshold right unilateral ECT versus minimally suprathreshold bilateral ECT: Antidepressant and memory effects. J ECT 18: 126– 129. 12394530
  71. [95]McCall WV, Reboussin DM, Weiner RD, Sackeim HA (2000): Titrated moderately suprathreshold vs fixed high-dose right unilateral electroconvulsive therapy: Acute antidepressant and cognitive effects. Arch Gen Psychiatry 57: 438– 444. 10807483
  72. [96]Ng C, Schweitzer I, Alexopoulos P, Celi E, Wong L, Tuckwell V, (2000): Efficacy and cognitive effects of right unilateral electroconvulsive therapy. J ECT 16: 370– 379. 11314875
  73. [97]Semkovska M, McLoughlin DM (2010): Objective cognitive performance associated with electroconvulsive therapy for depression: A systematic review and meta-analysis. Biol Psychiatry 68: 568– 577. 20673880
  74. [98]Brakemeier EL, Merkl A, Wilbertz G, Quante A, Regen F, Buhrsch N, (2014): Cognitive-behavioral therapy as continuation treatment to sustain response after electroconvulsive therapy in depression: A randomized controlled trial. Biol Psychiatry 76: 194– 202. 24462229
  75. [99]Fenton L, Fasula M, Ostroff R, Sanacora G (2006): Can cognitive behavioral therapy reduce relapse rates of depression after ECT? a preliminary study. J ECT 22: 196– 198. 16957536
  76. [100]Wilkinson ST, Ostroff RB, Sanacora G (2017): Computer-assisted cognitive behavior therapy to prevent relapse following electroconvulsive therapy. J ECT 33: 52– 57. 27564424 PMC5315599
  77. [101]Fitzgerald PB, Fountain S, Daskalakis ZJ (2006): A comprehensive review of the effects of rTMS on motor cortical excitability and inhibition. Clin Neurophysiol 117: 2584– 2596. 16890483
  78. [102]George MS, Lisanby SH, Avery D, McDonald WM, Durkalski V, Pavlicova M, (2010): Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: A sham-controlled randomized trial. Arch Gen Psychiatry 67: 507– 516. 20439832
  79. [104]O’Reardon JP, Solvason HB, Janicak PG, Sampson S, Isenberg KE, Nahas Z, (2007): Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: A multisite randomized controlled trial. Biol Psychiatry 62: 1208– 1216. 17573044
  80. [105]Lisanby SH, Husain MM, Rosenquist PB, Maixner D, Gutierrez R, Krystal A, (2009): Daily left prefrontal repetitive transcranial magnetic stimulation in the acute treatment of major depression: Clinical predictors of outcome in a multisite, randomized controlled clinical trial. Neuropsychopharmacology 34: 522– 534. 18704101
  81. [106]Berlim MT, Van den Eynde F, Jeff Daskalakis Z (2013): Clinically meaningful efficacy and acceptability of low-frequency repetitive transcranial magnetic stimulation (rTMS) for treating primary major depression: A meta-analysis of randomized, double-blind and sham-controlled trials. Neuropsychopharmacology 38: 543– 551. 23249815 PMC3572468
  82. [107]Brunoni AR, Chaimani A, Moffa AH, Razza LB, Gattaz WF, Daskalakis ZJ, (2017): Repetitive transcranial magnetic stimulation for the acute treatment of major depressive episodes: A systematic review with network meta-analysis. JAMA Psychiatry 74: 143– 152. 28030740
  83. [108]Dunner DL, Aaronson ST, Sackeim HA, Janicak PG, Carpenter LL, Boyadjis T, (2014): A multisite, naturalistic, observational study of transcranial magnetic stimulation for patients with pharmacoresistant major depressive disorder: Durability of benefit over a 1-year follow-up period. J Clin Psychiatry 75: 1394– 1401. 25271871
  84. [109]Moreines JL, McClintock SM, Holtzheimer PE (2011): Neuropsychologic effects of neuromodulation techniques for treatment-resistant depression: A review. Brain Stimul 4: 17– 27. 21255751 PMC3023999
  85. [110]Luber B, Lisanby SH (2014): Enhancement of human cognitive performance using transcranial magnetic stimulation (TMS). Neuroimage 85(Pt 3): 961– 970. 23770409 PMC4083569
  86. [112]Janicak PG, Dokucu ME (2015): Transcranial magnetic stimulation for the treatment of major depression. Neuropsychiatr Dis Treat 11: 1549– 1560. 26170668 PMC4492646
  87. [113]De Raedt R, Vanderhasselt MA, Baeken C (2015): Neurostimulation as an intervention for treatment resistant depression: From research on mechanisms towards targeted neurocognitive strategies. Clin Psychol Rev 41: 61– 69. 25468571
  88. [114]Lantrip C, Gunning FM, Flashman L, Roth RM, Holtzheimer PE (2017): Effects of transcranial magnetic stimulation on the cognitive control of emotion: Potential antidepressant mechanisms. J ECT 33: 73– 80. 28072659
  89. [115]Takano B, Drzezga A, Peller M, Sax I, Schwaiger M, Lee L, (2004): Short-term modulation of regional excitability and blood flow in human motor cortex following rapid-rate transcranial magnetic stimulation. Neuroimage 23: 849– 859. 15528085
  90. [116]Tegenthoff M, Ragert P, Pleger B, Schwenkreis P, Forster AF, Nicolas V, (2005): Improvement of tactile discrimination performance and enlargement of cortical somatosensory maps after 5 Hz rTMS. PLoS Biol 3: e362. 16218766 PMC1255742
  91. [118]Ridding MC, Rothwell JC (2007): Is there a future for therapeutic use of transcranial magnetic stimulation? Nat Rev Neurosci 8: 559– 567. 17565358
  92. [119]Hayashi T, Ohnishi T, Okabe S, Teramoto N, Nonaka Y, Watabe H, (2004): Long-term effect of motor cortical repetitive transcranial magnetic stimulation [correction]. Ann Neurol 56: 77– 85. 15236404
  93. [120]Gersner R, Kravetz E, Feil J, Pell G, Zangen A (2011): Long-term effects of repetitive transcranial magnetic stimulation on markers for neuroplasticity: Differential outcomes in anesthetized and awake animals. J Neurosci 31: 7521– 7526. 21593336 PMC6622610
  94. [122]Osuch EA, Benson BE, Luckenbaugh DA, Geraci M, Post RM, McCann U (2009): Repetitive TMS combined with exposure therapy for PTSD: A preliminary study. J Anxiety Disord 23: 54– 59. 18455908 PMC2693184
  95. [123]Isserles M, Shalev AY, Roth Y, Peri T, Kutz I, Zlotnick E, (2013): Effectiveness of deep transcranial magnetic stimulation combined with a brief exposure procedure in post-traumatic stress disorder–A pilot study. Brain Stimul 6: 377– 383. 22921765
  96. [124]Kozel FA, Motes MA, Didehbani N, DeLaRosa B, Bass C, Schraufnagel CD, (2018): Repetitive TMS to augment cognitive processing therapy in combat veterans of recent conflicts with PTSD: A randomized clinical trial. J Affect Disord 229: 506– 514. 29351885
  97. [125]Paulus W (2011): Transcranial electrical stimulation (tES - tDCS; tRNS, tACS) methods. Neuropsychol Rehabil 21: 602– 617. 21819181
  98. [126]Das S, Holland P, Frens MA, Donchin O (2016): Impact of transcranial direct current stimulation (tDCS) on neuronal functions. Front Neurosci 10: 550. 27965533 PMC5127836
  99. [127]Liebetanz D, Nitsche MA, Tergau F, Paulus W (2002): Pharmacological approach to the mechanisms of transcranial DC-stimulation-induced after-effects of human motor cortex excitability. Brain 125: 2238– 2247. 12244081
  100. [128]Nitsche MA, Jaussi W, Liebetanz D, Lang N, Tergau F, Paulus W (2004): Consolidation of human motor cortical neuroplasticity by D-cycloserine. Neuropsychopharmacology 29: 1573– 1578. 15199378
  101. [130]Loo CK, Husain MM, McDonald WM, Aaronson S, O’Reardon JP, Alonzo A, (2018): International randomized-controlled trial of transcranial direct current stimulation in depression. Brain Stimul 11: 125– 133. 29111077
  102. [131]Horvath JC, Forte JD, Carter O (2015): Quantitative review finds no evidence of cognitive effects in healthy populations from single-session transcranial direct current stimulation (tDCS). Brain Stimul 8: 535– 550. 25701175
  103. [132]Koster EHW, Hoorelbeke K, Onraedt T, Owens M, Derakshan N (2017): Cognitive control interventions for depression: A systematic review of findings from training studies. Clin Psychol Rev 53: 79– 92. 28273486
  104. [133]Segrave RA, Arnold S, Hoy K, Fitzgerald PB (2014): Concurrent cognitive control training augments the antidepressant efficacy of tDCS: A pilot study. Brain Stimul 7: 325– 331. 24486425
  105. [134]Brunoni AR, Boggio PS, De Raedt R, Bensenor IM, Lotufo PA, Namur V, (2014): Cognitive control therapy and transcranial direct current stimulation for depression: A randomized, double-blinded, controlled trial. J Affect Disord 162: 43– 49. 24767004
  106. [135]Bajbouj M, Aust S, Spies J, Herrera-Melendez AL, Mayer SV, Peters M, (2017): PsychotherapyPlus: Augmentation of cognitive behavioral therapy (CBT) with prefrontal transcranial direct current stimulation (tDCS) in major depressive disorder-study design and methodology of a multicenter double-blind randomized placebo-controlled trial [ published online ahead of print Dec 6]. Eur Arch Psychiatry Clin Neurosci. 29214483
  107. [136]Clarke PJ, Browning M, Hammond G, Notebaert L, MacLeod C (2014): The causal role of the dorsolateral prefrontal cortex in the modification of attentional bias: Evidence from transcranial direct current stimulation. Biol Psychiatry 76: 946– 952. 24690113
  108. [137]Saunders N, Downham R, Turman B, Kropotov J, Clark R, Yumash R, (2015): Working memory training with tDCS improves behavioral and neurophysiological symptoms in pilot group with post-traumatic stress disorder (PTSD) and with poor working memory. Neurocase 21: 271– 278. 24579831
  109. [138]Murrough JW, Abdallah CG, Mathew SJ (2017): Targeting glutamate signalling in depression: Progress and prospects. Nat Rev Drug Discov 16: 472– 486. 28303025

Cited by

Sorted by citations

Authors
Wilkinson, S. T., Holtzheimer, P. E., Gao, S., Kirwin, D. S., & Price, R. B.
Affiliations
  • Yale University (US)
  • Dartmouth College (US)
  • University of Pittsburgh (US)
Corresponding author
Price, Rebecca B.
ORCID
Venue
Biological Psychiatry
Publisher
Elsevier BV
Published
2019-03
Volume
85
Issue
6
Pages
454-465
ISSN
0006-3223 (ISSN-L)
DOI
10.1016/j.biopsych.2018.09.004
PMC
PMC6380941
OpenAlex
W2891291514
Cited by
95
References
27
Citations by year
2026: 13 · 2025: 8 · 2024: 16 · 2023: 18 · 2022: 15 · 2021: 11 · 2020: 6 · 2019: 7 · 2017: 1
FWCI
0.70
Type
journal article
Language
en
Open access
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Biological Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • Agency for Healthcare Research and Quality (K12HS023000)
  • Brain and Behavior Research Foundation
  • American Foundation for Suicide Prevention
  • National Institute of Mental Health (K23MH100259)
Topics
  • Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
  • Life Sciences › Neuroscience › Neurology › Transcranial Magnetic Stimulation Studies
  • Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
Keywords
neuroplasticity, depression, adaptive learning, cognitive behavioral therapy, ketamine, D-cycloserine, NMDA receptor modulators, electroconvulsive therapy, transcranial magnetic stimulation, treatment-resistant depression, relapse, mood disorders
MeSH terms
Antidepressive Agents, Behavior Therapy, Combined Modality Therapy, Depression, Electroconvulsive Therapy, Humans, Neuronal Plasticity, Transcranial Magnetic Stimulation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review